

Glioma

Recurrent

High Grade

Pre- Avastin

Surgical
Procedural
Candidates

FGFR1-3
Alteration

BRAF Mutation

[BRN0048](#)
[Phase I, First-In-Human, Multicenter, Open-Label Study of ABM-1310, Administered Orally in Adult Patients with Advanced Solid Tumors](#)

PI: Nagpal
Sponsor: ABM Therapeutics, Inc.

BRN0056
Phase I/II Dose-Escalation Study of Candidate GBM Vaccine VBI-1901 with Subsequent Extension of Optimal Dose in Recurrent GBM Subjects

PI: Nagpal
Sponsor: VBI Vaccines Inc.

BRN0054
Phase II Pemigatinib in Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations

PI: Lim
Sponsor: Incyte Corporation

BRN0042
Phase II/III Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM

PI: Recht
Sponsor: Pending

[CCT5061](#)
[Phase I Locoregionally \(LR\) Delivered Autologous B7-H3 Chimeric Antigen Receptor T Cells \(B7-H3CART\) in Recurrent Glioblastoma Multiforme \(GBM\)](#)

PI: Thomas
Sponsor: Stanford University




[BRN0045](#)
[Phase I/II Exablate Type 2 for BBBD With Microbubble Resonators in Tx of rGBM in Carboplatin Mono Treatment](#)




PI: Nagpal
Sponsor: InSightec, Inc.



BRN0049
Phase Ib Nivolumab or the Combination Nivolumab + Ipilimumab in Surgically Accessible Glioblastoma

PI: Lim
Sponsor: Pending

KEY

-  Pending
-  Open for Enrollment
-  Observational Study

-  Optional Path
-  Trial Posting
-  Enrollment on Hold

-  Extension Study
-  Immunotherapy